STS

Mass Megawatts (MMMW) Largest Sale of Solar Project with New Solar Tracker Targeted Completion in Early 2023 with Assistance of New Brownfield 10%Tax Credit Adder

Retrieved on: 
Thursday, September 15, 2022
Weather, Depreciation, Efficiency, Chevrolet Tracker (Americas), Mass Megawatts Wind Power, Brownfield land, Life, News, Altitude, Risk, OTC, Electricity, Technology, Wind, Goal, GLOBE, Marketing, STS, Patent, Renewable energy, Mass

The 30 percent investment tax credit and the additional 10 % adder for Brownfield development are important financing tools toward the completion of the solar project.

Key Points: 
  • The 30 percent investment tax credit and the additional 10 % adder for Brownfield development are important financing tools toward the completion of the solar project.
  • The solar project is projected to pay for itself in seven years based upon contracted electric prices packaged with current federal and state incentives.
  • The 500-kilowatt, project, Mass Megawatts largest to date, reduces the cost of solar power, while protecting the solar units by employing a furling technology borrowed from wind technology.
  • Mass Megawatts is responsible for the site development, fabrication, installation, and the interconnection of the project.

NASA Selects Firefly Space Transport Services (STS) as a Launch Provider for Venture-Class Acquisition of Dedicated and Rideshare (VADR) Missions

Retrieved on: 
Wednesday, September 14, 2022
Other Transport, Technology, Contracts, Transport, Satellite, Aerospace, Manufacturing, Government Technology, Defense, NASA, CubeSat, KSC, LLC, ISS, Northrop, Contract, Federal Aviation Administration, Partnership, Kennedy Space Center, Government, Grumman, Technology, Firefly, Vandenberg Space Force Base, Architecture, Science, National Aeronautics and Space Act, Research, Alpha, STS, Multimedia, LEO, CLPS, Communications satellite, Moon, Ridesharing

Firefly Space Transport Services (STS), a wholly-owned subsidiary of Firefly Aerospace, Inc, announced today that the company has been selected by the National Aeronautics and Space Administration (NASA) to provide launch services for the agencys Venture-Class Acquisition of Dedicated and Rideshare (VADR) missions in the 500-1000 kg grouping utilizing its Alpha rocket.

Key Points: 
  • Firefly Space Transport Services (STS), a wholly-owned subsidiary of Firefly Aerospace, Inc, announced today that the company has been selected by the National Aeronautics and Space Administration (NASA) to provide launch services for the agencys Venture-Class Acquisition of Dedicated and Rideshare (VADR) missions in the 500-1000 kg grouping utilizing its Alpha rocket.
  • Further, NASA noted that Firefly is the only launch vehicle provider in this grouping that has completed development and conducted its first test launch.
  • Firefly has had a long-standing relationship with NASA and is committed to providing NASA and other U.S. government entities with responsive, repeatable, reliable space transportation services, stated Jason Mello, President, Firefly STS, LLC.
  • Firefly is developing a family of launch and in-space vehicles and services that provide industry-leading affordability, convenience, and reliability.

Veritone Enhances its Multi-Award Winning AI-Driven Voice Solutions with Advanced Capabilities for Content Creators and Brands

Retrieved on: 
Wednesday, September 14, 2022
Technology, Audio, Video, Entertainment, Metaverse, Training, Film & Motion Pictures, Artificial Intelligence, Marketing, Software, Digital Marketing, Education, Communications, TV and Radio, Content Marketing, ROI, Software, Human voice, Efficiency, Lexicon, Emmy Awards, Organization, Radio, Acquisition, Compliance, News, Industry, Language, Intelligence, Terminology, IBC, Solution, Enterprise, Artificial intelligence, NASDAQ, Human, TikTok, Heart, TTS, STS, SEC, Multimedia, Speech technology, AI, Business, Mobile phone, Phonograph record, Telecommunication, Veritone, Mandalorians

The newest enhancements further advance Veritone Voice to give content creators and publishers one of the most powerful and versatile voice solutions on the market.

Key Points: 
  • The newest enhancements further advance Veritone Voice to give content creators and publishers one of the most powerful and versatile voice solutions on the market.
  • Addressing these needs is at the heart of our latest version of Veritone Voice, which empowers the voice to be articulate, genuine and nuanced for the content and audience.
  • Whether the voices are used for broadcast quality productions, the metaverse or other applications, we believe that content creators and brands will appreciate the authenticity our Veritone Voice solutions offer as they move their projects forward.
  • Since launching last year, Veritone Voice has attracted nearly 3,000 users who have generated synthetic voice clips used within the enterprise, consumer broadcast and metaverse environments.

South Star Battery Metals Announces Drilling & Exploration Program Update for Alabama Graphite Project and Geophysics Program for Santa Cruz Mine in Brazil

Retrieved on: 
Tuesday, September 13, 2022
PEA, Southeastern United States, ESG, TSX, Project, Diamond, OTCQB, Company, Acquisition, P.E, News, Program, TSX Venture Exchange, CEO, Goal, Techno-economic assessment, RC, Board, STS, National instrument, Metal, Education, Santa Claus, Lithium, BC, Pole star, Birmingham South Stars

The Alabama exploration program includes:

Key Points: 
  • The Alabama exploration program includes:
    Geotechnical Drilling / Installation of a Piezometer to Monitor Groundwater Levels; &
    Drill Pad Construction and Reclamation.
  • South Star Battery Metals Corp. is a Canadian battery metals project developer focused on the selective acquisition and development of near-term production projects in the Americas.
  • South Star's Santa Cruz Graphite Project, located in Southern Bahia, Brazil is the first of a series of industrial and battery metals projects that will be put into production.
  • South Star is executing on its plan to create a multi-asset, diversified battery metals company with near-term operations in strategic jurisdictions.

Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Retrieved on: 
Thursday, September 8, 2022
COVID-19, Security (finance), Human, Securities Exchange Act of 1934, Roswell Park Comprehensive Cancer Center, Securities Act of 1933, Form 10-K, STS, Virus, Risk, AML, LinkedIn, SEC, NY, Acute myeloid leukemia, U.S. Securities and Exchange Commission, Brain, Value, Antimetabolite, Company, Cancer, Twitter, Neoplasm, T-cell lymphoma, Terminology, Private Securities Litigation Reform Act, Forward-looking statement, Trial of the century, Pharmaceutical industry, Facebook

Details of the presentations are as follows:

Key Points: 
  • Details of the presentations are as follows:
    Title: The Value of Collaboration in Clinical Development: Experience from Poland
    For more information about the conference, visit: www.roswellpark.org/msc-symposium .
  • is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses.
  • The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
COVID-19, STS, Virus, AML, LinkedIn, Acute myeloid leukemia, Brain, Antimetabolite, Conference, Company, Cancer, Twitter, Neoplasm, T-cell lymphoma, Pharmaceutical industry, Vaccine, Facebook

HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Key Points: 
  • HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .
  • The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Bechtel and Cumulus: Increasing Productivity Through Digital Solutions

Retrieved on: 
Tuesday, September 6, 2022
Software, Partnership, CEO, Technology, Safety, Government, Engineering, Carbon, STS, Anchorage Air Route Traffic Control Center, Bechtel, Workflow, Digital Systems, Conference, Control center, Mobile app, Industry, Renewable energy, Satellite navigation device, Cumulus cloud

BOSTON, Sept. 6, 2022 /PRNewswire/ -- Cumulus Digital Systems, a global technology platform enabling connected work, today announced a successful partnership with Bechtel to deploy a bolted joint management system at scale. In addition to enforcing engineering controls and improving productivity, the deployment also successfully reduced the bolted connection leak rate to 0.1 percent, a 100 times reduction compared to the industry average of 10 percent.

Key Points: 
  • "The strong results from our partnership with Bechtel demonstrate the value that digitalization brings to construction," said Matthew Kleiman, CEO of Cumulus.
  • "We are excited to take this partnership even further and continue to use technology to eliminate rework and enable greater work transparency."
  • Furthering their commitment to reduce emissions and improve safety, Bechtel elected to implement Cumulus Smart Torque System (STS) during the construction of the Pennsylvania Chemicals project.
  • Bechtel has spent more than a century helping customers navigate shifts in energy consumption, technological change, financing challenges, and a sharpening focus on sustainable alternatives.

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Retrieved on: 
Tuesday, September 6, 2022
Neoplasm, Investigational New Drug, COVID-19, Security (finance), Human, GBM, Securities Exchange Act of 1934, Securities Act of 1933, Survival, Form 10-K, Degenerative disease, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, STS, Virus, Risk, Glioma, AML, Incidence, Person, Drug Quality and Security Act, Food, LinkedIn, Diagnosis, SEC, Acute myeloid leukemia, U.S. Securities and Exchange Commission, Brain, Antimetabolite, Company, FDA, Cancer, Twitter, T-cell lymphoma, Terminology, Glioblastoma, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry, Facebook

HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM").

Key Points: 
  • HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM").
  • "The receipt of Orphan Drug Designation represents an important milestone for our promising WP1122 development program," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.
  • Based on preclinical data indicating the potential for WP1122 as a treatment for GBM, Moleculin received Investigational New Drug status and is evaluating opportunities for collaboration in clinical development.
  • The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States.

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Retrieved on: 
Tuesday, September 6, 2022
Transfer, Technology, Australian Securities Exchange, Calendar, Pathology, Recurrence, APC, Agreement, Principal investigator, CD8, Urology, Antibody, GLOBE, Radiation, Sarcoma, Patient, Cancer, MHC II, Immunity, Government, Melanoma, Immutep, Department, Radiation therapy, Medical imaging, IMM, Monocyte, Autoimmune disease, NASDAQ, LAG-3, MHC, ASX, B cell, CMO, Maria, Macrophage, STS, Cardiothoracic surgery, Infection, General officer, Soft, Molecular medicine, Cell Research, Brachytherapy, Immune system, Pharmaceutical industry, Vaccine, Gastroenterology, Pembrolizumab

The trial will evaluate Immuteps lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).

Key Points: 
  • The trial will evaluate Immuteps lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).
  • Immutep will provide efti at no cost to the Maria Skodowska-Curie National Research Institute of Oncology and will technically support the trial.
  • The trial will be led by Principal Investigators, Dr. Katarzyna Kozak, M.D.
  • PhD., and Pawe Sobczuk, M.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skodowska-Curie National Research Institute of Oncology.

STS INKS INTRODUCES THE NEW 64" DIRECT TO FILM PRINTER

Retrieved on: 
Wednesday, August 31, 2022
Display resolution, STS, Maintenance, SAI, DTF, Lighting, LED, 3D printing

BOCA RATON, Fla., Aug. 31, 2022 /PRNewswire/ -- STS Inks, a global leader in the wide format, industrial and household inkjet ink market, today announced the launch of the STS XPJ-1682D 64" Direct to Film (DTF) Printer from Japan. The first units of the product will be distributed to dealers in the United States in September 2022. 

Key Points: 
  • The first units of the product will be distributed to dealers in the United States in September 2022.
  • The printer as SAI's Flexi DTF Edition RIP Software, bundled with Flexi DTF Editor.
  • "The printer is paired withSTS's DTF ink, which of course offers users excellent color gamut and outstanding durability."
  • STS Inks is the largest digital ink production company in the United States and global leader in the wide format, industrial and household inkjet ink market.